Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma

Xu, B

Xu, B (通讯作者),Univ South China, Coll Pharm, 28 Changsheng West Rd, Hengyang 421001, Hunan, Peoples R China.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022; 78 (5): 707

Abstract

Background Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin's lymphoma in the United States, with approximately 40% of fir......

Full Text Link